Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
News and updates for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) focus on its activities in neurological and rare diseases, including commercial performance and clinical development. Company press releases highlight revenue trends from its marketed medicines NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as guidance ranges for total revenues and net product sales.
Investors following ACAD news can see announcements of quarterly financial results, participation in major healthcare and investor conferences, and business updates presented at events such as the J.P. Morgan Healthcare Conference. These updates often describe how NUPLAZID and DAYBUE are performing commercially and how Acadia views the growth outlook for its neurology and neuro‑rare franchises.
Acadia’s news flow also covers regulatory and clinical milestones. Examples include U.S. Food and Drug Administration approval of DAYBUE STIX, a powder formulation of trofinetide for oral solution for Rett syndrome in adults and pediatric patients 2 years of age and older, approval of DAYBUE oral solution by the Ministry of Health in Israel, and progress toward regulatory opinions and late‑stage studies for trofinetide in other regions. The company issues updates on its pipeline, such as timelines for Phase 2 and Phase 3 trials of remlifanserin (ACP‑204) in Alzheimer’s disease psychosis and Lewy body dementia psychosis, and data presentations on ACP‑711 and NUPLAZID at scientific congresses.
Readers of this ACAD news page can use it to track Acadia’s financial disclosures, regulatory approvals, clinical trial readouts, and strategic commentary from management over time. The news archive provides context on how the company’s commercial portfolio and pipeline in central nervous system and neuro‑rare diseases are evolving.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Acadia Pharmaceuticals will announce its first quarter financial results on May 8, 2023, after market close. A conference call and webcast will occur on the same day at 4:30 p.m. Eastern Time for discussing these results and company operations. The call will be available on Acadia's website and archived until June 7, 2023. Acadia is recognized for its innovative therapies in neuroscience, particularly for conditions like Parkinson’s disease psychosis and Rett syndrome. The company continues to focus on developing solutions for negative symptoms of schizophrenia and Alzheimer’s-related issues. Investors should note that forward-looking statements regarding future events may contain risks and uncertainties that could affect actual results.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the presentation of four posters at the American Academy of Neurology (AAN) annual meeting from April 22 to 27, 2023, in Boston, Mass. The posters include a secondary analysis of communication-related endpoints from the Phase 3 LAVENDER™ study and an interim analysis of the DAFFODIL™ study. Notable presentations involve real-world physician surveys and an analysis of healthcare resource utilization in Rett syndrome patients. The poster P13 highlights the benefits of Trofinetide compared to placebo in communication abilities among individuals with Rett syndrome, thus showcasing the drug's potential. Rett syndrome is a rare neurological disorder affecting approximately 6,000 to 9,000 patients in the U.S., with Trofinetide being a key treatment option.
Acadia Pharmaceuticals has launched DAYBUE (trofinetide), the first FDA-approved therapy for Rett syndrome, a neurodevelopmental disorder affecting 6,000 to 9,000 patients in the U.S. The drug is available for individuals aged two and older and was officially approved on March 10, 2023. The company emphasizes its commitment to patient support, expanding the Acadia Connect program to enable access to this therapy through financial assistance and prescription support. Notable endorsements from healthcare professionals highlight DAYBUE's potential to improve symptoms and enhance patients' quality of life.
Common side effects include diarrhea (experienced by 85% of patients) and weight loss (12% had losses exceeding 7%). Acadia continues to focus on treatments addressing unmet medical needs in the field of neuroscience.